BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M. Simes, BioSanteâ€™s president & CEO, will present a corporate update at the 11th Annual BIO Investor Forum hosted by the Biotechnology Industry Organization (BIO). The BIO Investor Forum, which features leading private and emerging public companies, will take place October 9-10, 2012 at the Palace Hotel in San Francisco, CA.
A live audio webcast of remarks by Mr. Simes on October 10, 2012 at 10:30 am PDT may be accessed at http://www.veracast.com/webcasts/bio/investorforum2012/62205357.cfm. The webcast will be archived for 90 days.
The BIO Investor Forum is an international investor conference featuring leading private and emerging public biotech companies. Information about the conference is available at http://www.bio.org/events/conferences/11th-annual-bio-investor-forum.
About BioSante Pharmaceuticals, Inc.
BioSanteâ€™s corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies. BioSanteÂ´s products include LibiGelÂ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSanteÂ´s other products include an FDA-approved testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc., and the Pill-Plusâ„˘, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSanteÂ´s first FDA-approved product, Elestrinâ„˘ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, is marketed in the U.S. by Jazz Pharmaceuticals, BioSanteÂ´s licensee. Additional information is available online at: www.biosantepharma.com.Business Wire
Last updated on: 08/10/2012